A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Postherpetic Neuralgia

• Status: Completed
• Trial end date: 2008-08-19
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety of the long-term use of pregabalin.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Pregabalin

Criteria

Inclusion Criteria:

• Patients who completed the 13-week treatment of postherpetic neuralgia in Study A0081120.

• Patients must be able to understand and cooperate with study procedures and have signed a written informed consent prior to entering the study.

Exclusion Criteria:

• Patients who experienced serious adverse events in the preceding study (A0081120) that were determined by the investigator or the study sponsor to be causally related to the study medication.

• Patients exhibiting treatment non-compliance in the preceding study (A0081120)